These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 32966047)

  • 41. Toll-like receptor signaling in parasitic infections.
    Ashour DS
    Expert Rev Clin Immunol; 2015 Jun; 11(6):771-80. PubMed ID: 25896399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
    Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
    IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.
    Yu C; An M; Jones E; Liu H
    Pharm Res; 2018 Feb; 35(3):56. PubMed ID: 29423660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TLR agonists: our best frenemy in cancer immunotherapy.
    Kaczanowska S; Joseph AM; Davila E
    J Leukoc Biol; 2013 Jun; 93(6):847-63. PubMed ID: 23475577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting Toll-Like Receptors for Cancer Therapy.
    Braunstein MJ; Kucharczyk J; Adams S
    Target Oncol; 2018 Oct; 13(5):583-598. PubMed ID: 30229471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.
    Owen AM; Fults JB; Patil NK; Hernandez A; Bohannon JK
    Front Immunol; 2020; 11():622614. PubMed ID: 33679711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists.
    Andón FT; Leon S; Ummarino A; Redin E; Allavena P; Serrano D; Anfray C; Calvo A
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells.
    Nouri Y; Weinkove R; Perret R
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toll-like receptor agonists: a patent review (2011 - 2013).
    Hussein WM; Liu TY; Skwarczynski M; Toth I
    Expert Opin Ther Pat; 2014 Apr; 24(4):453-70. PubMed ID: 24456079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TLR-induced immunomodulatory cytokine expression by human gingival stem/progenitor cells.
    Mekhemar MK; Adam-Klages S; Kabelitz D; Dörfer CE; Fawzy El-Sayed KM
    Cell Immunol; 2018 Apr; 326():60-67. PubMed ID: 28093098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy.
    Jung E; Chung YH; Steinmetz NF
    Bioconjug Chem; 2023 Sep; 34(9):1596-1605. PubMed ID: 37611278
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy.
    Han S; Huang K; Gu Z; Wu J
    Nanoscale; 2020 Jan; 12(2):413-436. PubMed ID: 31829394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
    Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
    ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
    Shi M; Chen X; Ye K; Yao Y; Li Y
    Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity.
    Muraoka D; Harada N; Hayashi T; Tahara Y; Momose F; Sawada S; Mukai SA; Akiyoshi K; Shiku H
    ACS Nano; 2014 Sep; 8(9):9209-18. PubMed ID: 25180962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trial watch: Toll-like receptor ligands in cancer therapy.
    Le Naour J; Kroemer G
    Oncoimmunology; 2023; 12(1):2180237. PubMed ID: 36875550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.
    Noh JY; Yoon SR; Kim TD; Choi I; Jung H
    J Immunol Res; 2020; 2020():2045860. PubMed ID: 32377528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
    Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
    Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
    Corthals SL; Wynne K; She K; Shimizu H; Curman D; Garbutt K; Reid GS
    Br J Haematol; 2006 Feb; 132(4):452-8. PubMed ID: 16412017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.